Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06052345
Other study ID # 2022-04453-01
Secondary ID 965231
Status Recruiting
Phase
First received
Last updated
Start date March 31, 2024
Est. completion date September 2025

Study information

Verified date March 2024
Source Karolinska University Hospital
Contact Theodoros Foukakis, MD,PhD
Phone 0736896713
Email theodoros.foukakis@ki.se
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a single center prospective observational cohort study that aims to: - examine and identify possible risk and susceptibility factors for the incidence and progression of chemotherapy-induced polyneuropathy (CIPN) in female patients primarily operated for early non-metastatic breast cancer who will receive adjuvant chemotherapy containing paclitaxel - test different neurophysiological methods for early detection of CIPN - explore changes that underlie the development of CIPN in relation to clinical presentations, neurophysiological assessment, including measures of small nerve fiber dysfunction, and possible biochemical, metabolic and genetic associations - explore the effects of CIPN in the patient's lifestyle and quality of life for up to 12 months after the initiation of treatment


Description:

The patients who follow the inclusion criteria of the study will be asked to complete: - a baseline evaluation prior to receiving treatment. This will include a bedside clinical-neurological evaluation, nerve conduction studies (NCS) and quantitative sensory tests of thermal threshold (QST), blood sampling, an oral glucose tolerance test, a skin biopsy, and answering of questionnaires for assessment of symptoms of peripheral neuropathy as well as self-reports on their pre-treatment health and lifestyle status and cancer specific symptomatology - an on-treatment evaluation 4 weeks after the start of the treatment which will include NCS and QST - a post-treatment evaluation 4 weeks after the end of treatment which will include the evaluations stated above. During this visit the participants will be provided with the REBECCA lifestyle monitoring system which will include a smartwatch, installation of a mobile app and a PC plugin. The patients will be also asked to fill in some self-rated evaluations as in the pre-treatment period. Researchers, based on the outcomes of the participants, will divide them in two study groups A. CIPN-group and B. No CIPN which will be monitored with the REBECCA monitoring system. - a final evaluation. This will be performed 8 months after the post-treatment evaluation and it will include clinical-neurological evaluation, nerve conduction studies (NCS) and thermal threshold testing (QST). Additionally, the participants will be requested to fill in the same self-rated evaluations as in the baseline and the post-treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Female patients - Age of = 18 years - Newly operated primary breast cancer without metastatic disease receiving adjuvant chemotherapy containing paclitaxel - No prior chemotherapy other than cyclophosphamide and epirubicin - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 - Written informed consent - Able to communicate with investigators, participate in testing and comply with the requirements of the study-protocol Exclusion Criteria: - Have received drugs suspected/known to cause peripheral neuropathy - Have history of acquired or inherited neuropathy or other genetic disease with increased tendency to develop neuropathy - Have known disturbed glucose metabolism, either diabetes mellitus or impaired glucose tolerance - Have moderate to severe kidney, liver, lung or heart disease - Have known symptomatic or other advanced spinal stenosis - Have known autoimmune disease that potentially cause or contribute to neuropathy - Have known HIV or active HBV or HCV infections - Have known paraneoplastic syndrome - Have known alcohol abuse - Have known pregnancy or nursing

Study Design


Intervention

Device:
Garmin smartwatch
Physical activity (Activity sessions, type and length of activity, activity intensity estimations) Meal detection and meal characteristics (accelerometry and gyroscope data) Oxygen saturation (pulse oximetry) Number of steps (pedometer) Stress level indicators (based on heart-rate analytics) Sleep patterns (sleep and wake-up time, sleep quality)
Other:
REBECCA Mobile application
GPS positioning (daily location change patterns through pathway analysis and Point-of-interest analysis based on type-of-location automatic detection) Self-reports from patients and companions reports on mental and physical health, as well as periodic quality of life evaluations3 Patient self-uploaded pictures of meals (for evaluation of nutritional habits) and living environment stressors (for evaluation of living environment and self-perceived stressor analysis)
REBECCA PC plug-in
the developed plug-in monitors online activity, collecting anonymized data from web-browsers (Chrome) and social media (Facebook, Youtube and Instagram). These are relevant to current and historical data on: i) keywords in searches, ii) types of websites visited, iii) reactions to posts, iv) participation in online groups, v) types of bookmarked websites

Locations

Country Name City State
Sweden Karolinska University Hospital Solna Stockholm

Sponsors (3)

Lead Sponsor Collaborator
Theodoros Foukakis Centre for Research and Technology Hellas (CERTH), Karolinska Institutet

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of significant deterioration in neurophysiological parameters including alterations in morphology of small fibers or reduced IENFD (Intraepidermal Nerve Fiber Density) on first follow up visit and development of CIPN by performing detailed clinical neurophysiological examination and skin biopsies (where IENFD will be quantified) in different timepoints as described in the study protocol 1 year
Primary Correlation of abnormal laboratory tests in baseline assessment with development/severity of CIPN 1 year
Primary Correlation of parameters of NCS, temperature thresholds, and IENFD at baseline screening with development and severity of CIPN 1 year
Primary Biochemical and metabolic abnormalities prior to paclitaxel treatment and their association with the development of CIPN by performing blood tests, genotyping and skin biopsies 1 year
Secondary Calculate and compare the false negative and false positive rate of CIPN in every used method during follow up 1 year
Secondary Association of altered scoring in different questionnaires (Fact/GOG-Ntx, SFN-SIQ) and different examinations (UENS) with the presence and severity of CIPN 1 year
Secondary Evaluation of whether specific genotypes of breast cancer and higher or lower levels of different proteins are related with higher incidence rate and severity of CIPN by extracting DNA from blood samples and performing subsequent genotyping using SNP-array and GWAS. Also, by using proteomics analysis in blood samples and measure plasma levels of different proteins. 2 years
Secondary Study any correspondence between deterioration of QoL indicated by REBECCA monitoring system and standardized patient self-reported measures with diagnosed CIPN after implementation of different methods during follow up 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A